Niclosamide in prostate cancer: An inhibitor of AR-V7, a mitochondrial uncoupler, or more?
Author links open overlay panelMinasSakellakisabShow moreOutlineShareCite
doi.org/10.1016/j.ctarc.202... Get rights and contentUnder a Creative Commons licenseOpen accessHighlights
•A recent phase Ib study of reformulated niclosamide with abiraterone and prednisone in patients with advanced prostate cancer showed a promising preliminary efficacy signal with low toxicity.
•Niclosamide is one the first AR-V7 inhibitors to be tested in clinical trials.
•Preclinical findings suggest that AR-V7 inhibition alone cannot explain the magnitude of antitumor effects of niclosamide, either used alone or in combination with abiraterone or enzalutamide.
•Niclosamide, a well known mitochondrial uncoupler, has pleiotropic effects.
•The mechanism of action of reformulated niclosamide in patients with CRPC needs to be further investigated. This will potentially lead to new opportunities to develop and investigate even more selective and effective treatments against prostate cancer.